Physician profile
Jordan D Smith
NPI 1225292139
$1,213.20
in general payments reported to CMS, 2019-2025
14 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.72 · 2020: $61.89 · 2021: $189 · 2022: $185 · 2023: $279 · 2024: $234 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $249.13 | 2022-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $204.90 | 2022-2024 | Cequa |
| Allergan, INC. | $157.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $137.38 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $124.91 | 2024-2025 | Xdemvy |
| Abbvie INC. | $85.81 | 2022-2023 | Durysta, Vuity, Lumigan |
| Oyster Point Pharma, INC. | $72.28 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $42.75 | 2025 | |
| Harrow Eye, LLC | $32.67 | 2024 | Vevye |
| Shire North American Group INC | $30.92 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.58 | 2021 | |
| Abbott Laboratories | $22.60 | 2025 | Freestyle Libre 3 |
| Alcon Vision LLC | $15.36 | 2025 | Rocklatan |
| Eyevance Pharmaceuticals LLC | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.